Scarica l'app Stockscreener
11.45
0.35%
-0.04
Dopo l'orario di chiusura:
11.45
Helus Pharma Inc Borsa (HELP) Ultime notizie
Cybin Stock Builds Bullish Momentum as Clinical Catalysts Strengthen the HELP Outlook - kalkine.ca
Helus Pharma at Canaccord Genuity growth conference: phase iii test looms - Investing.com Canada
Adage Capital reports 5.29% Cybin Inc. (HELP) ownership, 3.29M shares - Stock Titan
Cybin D/B/A Helus Pharma (HELP) Stock Price, News, Quote & History - Yahoo! Finance Canada
FDA Fast-Tracks Psychedelic Research After Trump’s Executive Order — CMPS, HELP Stocks Gain - Stocktwits
Helus Pharma (HELP) CEO to Join Canaccord Genuity Growth Conference Fireside Chat - Stock Titan
Cybin’s Helus Pharma to join Canaccord Genuity Annual Growth Conference fireside chat - Bitget
Helus Pharma to Participate at the Canaccord Genuity 46th Annual Growth Conference in BostonMon, 08/10/202612:00 - Helus Pharma
Cybin (HELP) Names New CEO, Is The Stock Still Cheap? - Yahoo! Finance Canada
Cybin (HELP) Is Up 33.1% After Hiring Helus Veteran Michael Halstead As CEO – Has The Bull Case Changed? - Yahoo Finance
Cybin (Helus Pharma, HELP) Leaps 14% Ahead of Pivotal Depression Trial Data - kalkine.ca
Could Helus Pharma’s New CEO Reframe Cybin’s (HELP) Path From Clinical Trials To Commercial Scale? - simplywall.st
Helus Pharma Shares Rise After Appointing New CEO - Moomoo
A CEO With a Proven Track Record of Success in Growing and Scaling Biopharmaceutical Companies Just Appointed CEO at a Clinical-Stage Biotech, Months Before Its Pivotal Phase 3 Readout - The Manila Times
A CEO With a Proven Track Record of Success in Growing and Scaling Biopharmaceutical Companies ... - Caledonian Record
A CEO With a Proven Track Record of Success in Growing and - GlobeNewswire
Helus Pharma appoints Michael Halstead as chief executive - Investing.com
Helus Pharma Appoints Michael Halstead as Chief Executive Officer - The Manila Times
Helus Pharma appoints Michael Halstead as chief executive By Investing.com - Investing.com India
Helus Pharma (HELP.NE) Names Michael Halstead CEO Ahead of Phase 3 HLP003 Data Readout - kalkine.ca
HELP Stock Price and Chart — NEO:HELP - tradingview.com
HELP Initiated Coverage by Wells Fargo -- Rating Set to Overweig - GuruFocus
HELP Initiated Coverage by Wells Fargo -- Rating Set to Overweight - GuruFocus
Helus Pharma Price Target Announced at $16.00/Share by Wells Fargo - Moomoo
Cybin (CYBN) Stock Fair Value Moves Lower As Analysts Rework Psychedelic Sector Assumptions - Yahoo Finance
Cybin D/B/A Helus Pharma (HELP.NE) Stock Price, News, Quote & History - Yahoo! Finance Canada
Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ), Helus Pharma (HELP) and Nektar Therapeutics (NKTR) - The Globe and Mail
Cybin D/B/A Helus Pharma (HELP) stock price, news, quote and history - Yahoo Finance UK
Cybin D/B/A Helus Pharma (HELP.NE) stock price, news, quote and history - Yahoo Finance UK
HELP: Helus Pharma Inc. Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
symbol__ Stock Quote Price and Forecast - CNN
H.C. Wainwright reiterates Helus Pharma stock rating on trial enrollment By Investing.com - Investing.com Canada
Helus Pharma Inc. (HELP) News, Articles, Events & Latest Updates - Stocktwits
Helus Pharma (HELP) Achieves Enrollment Milestone in Phase 3 Stu - GuruFocus
HELP Stock Surges To Over 6-Month Highs Led By Crucial Phase 3 Milestone – Retail Expects It To Hit Fresh 52-Week Highs - Yahoo Finance
Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of H - GuruFocus
Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule - Nasdaq
Helus Pharma stock jumps on Phase 3 enrollment completion By Investing.com - Investing.com Canada
A Depression Drug Just Cleared a Key Hurdle Early, and the Market for New Mental Health Treatments Keeps Widening - Cantech Letter
Helus Pharma completes enrollment in Phase 3 tr... - Pluang
Chief Financial Officer Greg Cavers Sold A Bunch Of Shares In Cybin - simplywall.st
Cybin (HELP) Advances Psychedelic Depression Drug to Phase 3 Amid Fresh Funding – What Really Matters? - simplywall.st
Big Pharma Just Paid Up to $3.8 Billion for Psychedelic Medicine, and the Rest of the Sector Is Being Repriced in Real Time - Finansavisen
Cybin (HELP) Is Up 6.2% After Advancing HLP003 To Phase 3 And Raising US$50 Million - Yahoo Finance
Helus Pharma (Nasdaq: HELP) closes US$50M underwritten share offering - Stock Titan
Is Cybin D/B/A Helus Pharma (HELP) Stock a Psychedelic Medicine Opportunity Ahead of HLP003 Trial Results? - Yahoo Finance
0.03%
0.33%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):